Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_01976 |
| Species: | Homo sapiens |
| Position : | chr14:92920852-92922852 |
| Year: | 2018 |
| Title: | Conventional and Neo-antigenic Peptides Presented by beta Cells Are Targeted by Circulating Na?ve CD8+ T Cells in Type 1 Diabetic and Healthy Donors |
| Genome Build: | hg38 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | cervical cancer |
| PMID: | 30078552 |
| MONDO: | MONDO:0001156 |
| Tissue: | Cervix |
| Tissue Ontology ID: | UBERON:0000002 |
| Cell Source: | HeLa cell |
| CVCL ID: | CVCL_0030 |
| Cell Type: | cervical adenocarcinoma cell |
| Cell Ontology ID: | CL:0000069 |
| Experiment Type: | Enhancer activity assay |
| High Throughput Method: | RNA-seq |
| Low Throughput Method: | 3C, Immunofluorescence, RT-PCR, RT-RT-qPCR |
| Target gene : | PTPRN |
| TF name : |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|